Alteogen lands $149M convertible from Korean growth fund, Skylake
What's the deal? South Korea's AlteogenDealroom has a profile for this one. Try Dealroom → is raising US$167.7M through a post-IPO convertible issuance backed by the National Growth Fund and Skylake Equity PartnersDealroom has a profile for this one. Try Dealroom →. The investors are buying in via SkyAlt, a vehicle the two set up to match their commitments. Alteogen said it will use the money to build new production facilities and acquire products and technologies.
How it's structured: The round splits into US$83.8M of convertible preferred stock and US$83.8M of redeemable convertible preferred stock. The redeemable shares were priced at a 10.3% premium to the reference price.
What's the endgame? Alteogen wants to expand manufacturing capacity and diversify its pipeline on the back of ALT-B4, the core material in its Hybrozyme platform for converting drugs to subcutaneous injection. That technology underpins licensing deals with 10 global drugmakers, including MSD, AstraZeneca, Sanofi, Novartis, and GSK.
Why it matters: MSD's subcutaneous version of Keytruda, which uses ALT-B4, is approved and launched in the US, Europe, Canada, South Korea, and Japan. Alteogen expects continued sales milestone and royalty income as commercialisation widens.
Chief executive officer Jeon Tae-yeon said the firm aims to "secure products and technologies with high growth potential quickly and expand its future business base" (translated from Korean).
The backers: The National Growth Fund is a policy fund set up to supply long-term capital to advanced strategic and future growth industries. Skylake manages about US$2.93B and was named a large-league general partner for the National Growth Fund in 2026, securing roughly US$167.7M in policy capital.
Min Hyun-ki, Skylake's chief executive officer, said Alteogen "leads the domestic bio industry based on differentiated technology" and had built "a competitive business model capable of continuous growth" around ALT-B4 (translated from Korean).
The signal: The deal shows Korean state-backed policy capital flowing into a homegrown biotech with proven global licensing traction, betting that platform royalties can fund the next wave of pipeline expansion.
Read more: edaily.co.kr
Image credit: Generated with Gemini
